TOURMALINE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.19 USD | +3.65% |
|
+16.39% | -38.16% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 532.4 | 400.6 | - | - |
| Enterprise Value (EV) 1 | 532.4 | 89.9 | -29.1 | 83.1 |
| P/E ratio | -2.95 x | -5.42 x | -5.07 x | -4.33 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 40.1 x | 33.4 x |
| EV / Revenue | - | - | -2.91 x | 6.92 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -1.28 x | 0.42 x | -1.3 x |
| FCF Yield | - | -77.9% | 241% | -77% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 20,337 | 25,647 | - | - |
| Reference price 2 | 26.18 | 16.19 | 16.19 | 16.19 |
| Announcement Date | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 10 | 12 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -45.41 | -80.11 | -91.93 | -111.3 |
| Operating Margin | - | - | - | -919.28% | -927.55% |
| Earnings before Tax (EBT) 1 | - | -42.12 | -78.07 | -109.8 | -121.5 |
| Net income 1 | -19.7 | -42.12 | -73.3 | -91.17 | -112.3 |
| Net margin | - | - | - | -911.68% | -935.7% |
| EPS 2 | -1.790 | -8.870 | -2.986 | -3.192 | -3.738 |
| Free Cash Flow 1 | - | - | -70 | -70 | -64 |
| FCF margin | - | - | - | -700% | -533.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 7/20/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -8.932 | -14.89 | -17.52 | -19.43 | -20.66 | -22.59 | -20.3 | -21.99 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.015 | -12.9 | -13.31 | -19.82 | -21.13 | -24.25 | -20.3 | -21.99 |
| Net income 1 | -7.015 | -12.9 | -13.31 | -18.37 | -19.44 | -21.57 | -20.3 | -21.99 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -1.640 | -0.8100 | -0.5500 | -0.7220 | -0.7640 | -0.8400 | -0.8300 | -0.9000 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/14/23 | 3/19/24 | 5/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 311 | 430 | 318 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -70 | -70 | -64 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | -5.920 | - | - | - |
| Capex 1 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 7/20/23 | 3/19/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
15.62
USD
Average target price
58.33
USD
Spread / Average Target
+273.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.16% | 401M | |
| +16.93% | 124B | |
| +17.01% | 109B | |
| -7.23% | 23.84B | |
| +1.98% | 22.42B | |
| -14.29% | 17.5B | |
| -6.79% | 16.61B | |
| -37.63% | 16.43B | |
| +2.17% | 13.4B | |
| +24.42% | 11.47B |
- Stock Market
- Equities
- TRML Stock
- Financials Tourmaline Bio, Inc.
